|
Market Closed -
Nasdaq Stockholm
16:30:00 30/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.009900 SEK | -1.00% |
|
-1.98% | -97.06% |
| 10-28 | Alligator Bioscience proposes reverse split | FW |
| 10-22 | Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Company Valuation: Alligator Bioscience AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 566.9 | 341.9 | 453.3 | 189.2 | 14.76 | 6.218 |
| Change | - | -39.69% | 32.59% | -58.27% | -92.2% | -57.87% |
| Enterprise Value (EV) | 298.5 | 269.1 | 403.3 | 168.4 | 14.76 | 6.218 |
| Change | - | -9.85% | 49.87% | -58.24% | -91.24% | -57.87% |
| P/E | -4.02x | -1.76x | -1.25x | - | - | - |
| PBR | 2.01x | 3.88x | 34.5x | - | - | - |
| PEG | - | -0x | 0x | - | - | - |
| Capitalization / Revenue | 37.5x | 9.21x | 7.32x | 3.17x | 2.3x | 5.18x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 5.18x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.07x |
| EV / EBIT | -0x | -0x | -0x | - | -0x | -0.07x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -640 | -880 | -550 | - | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 15.13 | 37.14 | 61.9 | 59.71 | 6.421 | 1.2 |
| EBITDA 1 | -130.4 | -181 | -238.5 | -180.4 | -105.8 | -91.9 |
| EBIT 1 | -141.6 | -192.8 | -249 | - | -116.1 | -94.4 |
| Net income 1 | -141.7 | -193.4 | -248.6 | -233.9 | -51.35 | -94.4 |
| Net Debt | -268.4 | -72.8 | -50.02 | -20.74 | - | - |
| Reference price 2 | 2,570.000000 | 1,550.000000 | 689.000000 | 249.000000 | 0.336900 | 0.009900 |
| Nbr of stocks (in thousands) | 221 | 221 | 658 | 760 | 43,814 | 628,107 |
| Announcement Date | 11/02/22 | 10/02/23 | 08/02/24 | 22/01/25 | 12/02/26 | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 633K | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 18.13x | 28.02x | 6.57x | 0.34% | 39.43B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATORX Stock
- Valuation Alligator Bioscience AB
Select your edition
All financial news and data tailored to specific country editions
